To provide support for AIDS vaccine development through provision of key
reagents.Maintenance of repository of high quality, specialised research reagents.To provide novel reagents to facilitate exploitation of new lines of vaccine
research.To promote multi-centre European AIDS vaccine research clusters such as
EuroVac.To support pre-clinical studies of candidate vaccines in animal models.To support clinical studies of candidate vaccines in man.
Programme EVA CFAR: An extensive and valuable inventory of over 1900 ‘state
of the art’ reagents, most of which are not available commercially, has been
built up at the CFAR repository at NIBSC.
Provision of reagents: The provision of key reagents is a highly effective
way of supporting and enhancing vaccine research and one where European
added-value has true meaning and can be readily demonstrated. During the second
year, over 4 900 reagents were distributed to 572 scientists, a 20% increase
over year one.
Pre-clinical research: High priority has continued to be given to the support
of pre-clinical vaccine studies with the SIV-macaque model, through the
provision of reagents and directed support for the European Network for Vaccine
Evaluation in Primates (ENVEP).
SHIV (HIV-SIV) chimaeras for vaccine challenge experiments: The development
of SHIV chimaeric viruses carrying HIV envelopes from a range of strains has
continued to be supported, so that HIV vaccines designed for man can be
evaluated in the macaque model.
DNA vaccines: Support has been provided for the development and production of
a variety of DNA vaccines using different genes and expression systems to
achieve a reproducible and durable immune response.
Recombinant viral vectors: Programme EVA has supported the development of
vaccines based on recombinant viral vectors such as the modified vaccinia Ankara
and Semliki forest virus vectors, and has prepared batches of immunogens for
collaborative vaccine studies.
Immunological and virological reagents for vaccine studies: Reagents,
such as recombinant proteins, peptides and viral isolates, are provided by EVA
for a wide range of immunological and virological studies.
Preparation of vaccines and reagents for use in clinical studies: As well as
supporting preclinical evaluation of vaccine strategies, the programme is
becoming increasingly involved in the support of clinical studies in man through
the provision of key reagents. EuroVac is being provided with overlapping HIV-1
subtype C gag and nef peptides for analysing the cellular immune responses of
- H. Wigzell, Karolinska Institute, SE-Stockholm, Sweden
- A. Burny, Université Libre de Bruxelles, BE-Brussels, Belgium
- M. Esteban, Centro Nacional de Biotecnologia, ES-Madrid, Spain
- V. Erfle, GSF, DE-Neuherberg, Germany
- M. Girard, Centre de Recherche, Merieux-Pasteur Lyon, FR-Lyon, France
- J. Goudsmit, University of Amsterdam, NL-Amsterdam, The Netherlands
- G. Hunsmann, Deutsches Primatenzentrum (DPZ), DE-Goettingen, Germany
- K. Krohn, University of Tampere, FI-Tampere, Finland
- L Montagnier, Institute Pasteur, FR-Paris, France
- M. Papamichail, Helenic Anti-Cancer Institute, EL-Athens, Greece
- A. Siccardi, DIBIT, Istituto H San Rafaele, IT-Milan, Italy
- G. Schild, NIBSC, Potters Bar, Hertfordshire, United Kingdom